Study Evaluating the Safety and Tolerability of NSA-789
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy
In brief
This is the first time that NSA-789, a new compound being developed for schizophrenia, will be given to humans. Each healthy subject will receive a single dose, except for 8 subjects who will receive 2 doses-- one dose under fasting conditions and one dose after eating food.
Key facts
- Study ID
- NCT00633048
- Run by
- Wyeth is now a wholly owned subsidiary of Pfizer
- People needed
- 64
- Starts
- 2008-03-01
- Expected to finish
- 2008-05-01
- Last updated by the study team
- 2009-02-17
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Tacoma, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.